NeoGraph Analytics
PharmaceuticalsNorth America2023 – 2032

Global Biosimilars Market Size, Share and Trends Analysis

Explore the global biosimilars market size of $26.5B in 2023, projected to reach $89.6B by 2032 at a 14.5% CAGR.

Revenue, 2023

$26.5B

Forecast, 2032

$89.6B

CAGR, 2024-2032

14.5%

Report Coverage

North America

Code: biosimilars-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

The global biosimilars market, valued at $26.5 billion in 2023, is projected to reach $89.6 billion by 2032, growing at a CAGR of 14.5%. Rising demand for affordable biologics, expiring patents on blockbuster drugs, and supportive regulatory frameworks are primary growth catalysts. North America leads with 42% market share, while Asia Pacific emerges as the fastest-growing region at 18.5% CAGR. Key players like Sandoz, Celltrion, and Biocon are expanding portfolios aggressively. Oncology and autoimmune disease applications dominate therapeutic segments. The market presents significant investment opportunities in emerging economies and next-generation complex biosimilars.

02

Key Highlights

1

Market projected to grow from $26.5B to $89.6B by 2032 at 14.5% CAGR.

2

North America leads with 42% share; Asia Pacific fastest growing at 18.5% CAGR.

3

Monoclonal antibodies dominate product type segment with 40% market share.

03

Market Overview

Market Context

The biosimilars market is experiencing rapid expansion as blockbuster biologic patents expire and healthcare systems worldwide seek cost-effective treatment alternatives. Regulatory harmonization and increasing clinical evidence supporting biosimilar safety and efficacy continue to accelerate global adoption across developed and emerging markets.

The global biosimilars market reached $26.5 billion in 2023 and is forecast to hit $89.6 billion by 2032. Growth is driven by patent expirations of major biologics, cost containment pressures, and expanding regulatory pathways worldwide.

Market Stage

High growth

Adoption Level

Growing

Key Trends

Increasing patent expirations of blockbuster biologics driving biosimilar launchesRegulatory harmonization across emerging markets accelerating approvalsGrowing adoption of interchangeable biosimilars in the United StatesRising focus on complex biosimilars beyond monoclonal antibodies
04

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 14.5%

Base Year (2023)

$26.5B

Forecast (2032)

$89.6B

CAGR (2024-2032)

14.5%

Market size by year, 2024-2032, in USD Billion.
YearMarket size ($ Billion)
2023Base year$26.50B
2024$30.34B
2025$34.74B
2026$39.78B
2027$45.55B
2028$52.15B
2029$59.71B
2030$68.37B
2031$78.29B
2032$89.64B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Forecast Analysis

Sustained double-digit growth is expected through 2032, driven by expanding patent cliffs, rising chronic disease burden, and increasing regulatory approvals. Oncology and autoimmune segments will lead demand. Asia Pacific will witness the fastest growth due to improving healthcare infrastructure and local manufacturing capabilities.

Regional Market Analysis
Market share and growth rate by region
Regional market analysis — market share, growth rate and largest market by region.
RegionMarket shareGrowth rateLargest market
North America42.0%13.8%United States
Europe30.0%12.5%Germany
Asia Pacific28.0%18.5%China

North America

#1
Share: 42.0%CAGR: 13.8%

Largest market: United States

Europe

#2
Share: 30.0%CAGR: 12.5%

Largest market: Germany

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
05

Market Dynamics

  • Patent expirations of major biologic drugs creating market opportunities
  • Cost-effective alternatives demanded by healthcare payers globally
  • Supportive regulatory frameworks and fast-track approval pathways
06

Market Segmentation

By Type
Market share distribution across 4 segments
By Type — market share by segment, in percent.
SegmentShare
Monoclonal AntibodiesLargest segment driven by blockbuster biologic patent expirations in oncology and autoimmune diseases.40.0%
Recombinant ProteinsIncludes insulin and growth factor biosimilars with growing diabetes prevalence.28.0%
PeptidesEmerging segment with increasing applications in metabolic and endocrine disorders.15.0%
OthersIncludes vaccines, blood products, and other biologic subtypes gaining traction.17.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
By Application
Market share distribution across 5 segments
By Application — market share by segment, in percent.
SegmentShare
OncologyDominant application area with multiple approved biosimilar monoclonal antibodies.35.0%
Autoimmune DiseasesRapidly growing segment driven by adalimumab and infliximab biosimilar adoption.25.0%
DiabetesInsulin biosimilars gaining significant market share amid rising diabetes prevalence.18.0%
Growth DisordersRecombinant growth hormone biosimilars expanding patient access globally.12.0%
OthersIncludes cardiovascular, ophthalmology, and hematology applications.10.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.

By End User

  • Hospitals
  • Specialty Clinics
  • Retail Pharmacies
  • Research Institutes
07

Regional Analysis

1

North America

Lead: United States
CAGR: 13.8%Share: 42.0%

Dominant market driven by FDA interchangeability designations and strong biosimilar uptake.

2

Europe

Lead: Germany
CAGR: 12.5%Share: 30.0%

Mature regulatory environment with the EMA leading biosimilar approvals since early 2006.

3

Asia Pacific

Lead: China
CAGR: 18.5%Share: 28.0%

Fastest-growing region fueled by expanding healthcare access and local manufacturing capabilities.

Country-Level Analysis

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Market share and growth rate by country
CountryShareGrowth
United States
38.0%
+14.2%
Germany
15.0%
+11.8%
China
14.0%
+20.3%
08

Competitive Landscape

S

Sandoz

Switzerland

Leader10B

Pioneering biosimilars developer with the broadest global portfolio and extensive regulatory experience across multiple markets.

Swiss-headquartered global pharmaceutical leader and pioneer in biosimilars with the industry's broadest approved portfolio.

C

Celltrion

South Korea

Challenger3.2B

Leading Asian biosimilar manufacturer with a robust pipeline and strong presence in oncology and immunology biosimilars.

South Korean biopharmaceutical company specializing in biosimilar development, manufacturing, and commercialization with a strong oncology pipeline.

B

Biocon

India

Follower1.5B

India-based biologics company rapidly expanding its biosimilar portfolio with growing presence in regulated markets.

India's largest biopharmaceutical company with a growing biosimilars portfolio targeting oncology, diabetes, and autoimmune diseases.

09

Recent Developments

25
2025Amgen

Received FDA approval for multiple interchangeable biosimilars expanding patient access to affordable biologics.

24
2024Celltrion

Launched Yuflyma (adalimumab biosimilar) in the United States and European markets, strengthening its global biosimilar portfolio.

10

Regulatory Landscape

FDA Biosimilar Action Plan encouraging interchangeable biosimilar approvals in the United StatesEMA's well-established biosimilar framework serving as a global regulatory benchmark since 2006
11

Research Methodology

Primary research

  • Expert interviews
  • Surveys

Secondary research

  • Industry reports
  • Company financials

Validation: Triangulation method

12

Strategic Takeaways

Investors

The biosimilars market offers high-growth potential with a 14.5% CAGR through 2032, particularly in emerging markets.

Operators

Focus on complex biosimilars and interchangeable designations to capture premium pricing and market differentiation.

13

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.